Societe Generale analyst Delphine Le Louet downgrades Alcon (NYSE:ALC) from Hold to Sell.
Merck’s WELIREG Advances in FDA Review, Offering New Hope for Advanced Renal Cell Carcinoma Patients
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental new drug application (sNDA)
